Arsanis

About Arsanis

Arsanis, Inc. was a clinical-stage biopharmaceutical company that concentrated on applying monoclonal antibody (mAb) immunotherapies to combat serious infectious diseases. The company was co-founded in the fall of 2010 by Dr. Eszter Nagy, a former SVP of Research at Intercell AG; Dr. Tillman Gerngross, a serial entrepreneur and professor of bioengineering at Dartmouth College; and Errik Anderson, then COO of Adimab. Their collective expertise in mAb discovery, infectious disease biology, and commercialization shaped the company's direction. Dr. Nagy, serving as Chief Scientific Officer, led the research and preclinical development from the company's subsidiary in Vienna, Austria. Dr. Gerngross, with a track record of founding successful biotech firms like GlycoFi (acquired by Merck) and Adimab, served as Chairman of the Board.

The company's business was centered on developing targeted immunotherapies as an alternative to traditional antibiotics, aiming to address the growing threat of antimicrobial resistance. Its approach involved creating highly specific mAbs that could neutralize pathogens or their toxins directly, thereby preventing infection and treating diseases while minimizing damage to the host's microbiome. The primary clients for these therapies would have been hospitals and healthcare providers managing high-risk patients, such as those on mechanical ventilation. Arsanis operated with a U.S. headquarters in Waltham, Massachusetts, and its main research and development facility in Vienna, Austria.

Arsanis' lead product candidate was ASN100, a combination of two human monoclonal antibodies designed to neutralize six key toxins produced by Staphylococcus aureus (S. aureus), a leading cause of hospital-acquired infections. This product was intended for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients, an indication for which it received Fast Track designation from the U.S. FDA in 2016. The company advanced ASN100 into a Phase 2 clinical trial. However, in June 2018, Arsanis discontinued the trial after a planned interim analysis concluded the study was unlikely to meet its primary efficacy endpoint. Following this significant setback, Arsanis conducted a strategic review and, in November 2018, entered into a definitive agreement for a reverse merger with the privately-held X4 Pharmaceuticals. The all-stock transaction, completed in March 2019, resulted in a combined company operating under the X4 Pharmaceuticals name, shifting focus to therapies for rare diseases and cancer.